InnoSIGN Management Company BV

InnoSIGN Management Company BV appears to be the management entity for InnoSIGN, a precision medicine company based in Eindhoven, Netherlands. InnoSIGN, co-founded by Paul van de Wiel and Sigi Neerken, develops mRNA-based pathway activity profiling technology designed to revolutionize precision medicine by obtaining more insight into the mechanisms of disease, with a focus on supporting diagnostics and drug development in oncology. The company was spun out from Royal Philips in March 2022 and has successfully raised $8M in Series A funding from investors such as Casdin Capital, Life Science Angels, Thuja Capital, and Brabant Development Agency (BOM). While the prompt requested an investor profile, the available information indicates InnoSIGN Management Company BV is part of an operating company that receives investment, rather than an entity that makes investments. Consequently, specific investment-related details are not applicable.